TY - JOUR AU - Tuka, Bernadett AU - Körtési, Tamás AU - Nánási, Nikolett AU - Tömösi, Ferenc AU - Janáky, Tamás AU - Veréb, Dániel AU - Szok, Délia AU - Tajti, János AU - Vécsei, László TI - Cluster headache and kynurenines JF - JOURNAL OF HEADACHE AND PAIN J2 - J HEADACHE PAIN VL - 24 PY - 2023 IS - 1 PG - 11 SN - 1129-2369 DO - 10.1186/s10194-023-01570-9 UR - https://m2.mtmt.hu/api/publication/33734067 ID - 33734067 N1 - ELKH-SZTE Neuroscience Research Group, Department of Neurology, Faculty of Medicine, University of Szeged, Semmelweis U 6, Szeged, 6725, Hungary Department of Radiology, Faculty of Medicine, University of Szeged, Szeged, Hungary Faculty of Health Sciences and Social Studies, University of Szeged, Szeged, Hungary Department of Medical Chemistry, Interdisciplinary Excellence Centre, University of Szeged, Szeged, Hungary Department of Neurology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary Cited By :1 Export Date: 21 January 2024 CODEN: JHPOA Correspondence Address: Vécsei, L.; ELKH-SZTE Neuroscience Research Group, Semmelweis U 6, Hungary; email: vecsei.laszlo@med.u-szeged.hu Chemicals/CAS: 3 hydroxyanthranilic acid, 548-93-6; 3 hydroxykynurenine, 484-78-6; 5 hydroxyindoleacetic acid, 1321-73-9, 54-16-0; anthranilic acid, 118-92-3; kynurenic acid, 492-27-3; kynurenine, 16055-80-4, 343-65-7; picolinic acid, 3198-27-4, 98-98-6, 88161-53-9; quinolinic acid, 89-00-9; serotonin, 50-67-9; tryptophan, 6912-86-3, 73-22-3; xanthurenic acid, 59-00-7; Kynurenic Acid; Kynurenine; Tryptophan Funding details: 0 T 204 2939/211, UNKP-22–4 Funding details: Magyar Tudományos Akadémia, MTA, 5706 Funding details: Innovációs és Technológiai Minisztérium, NKFIH-1279–2/2020 TKP2020 Funding text 1: Open access funding provided by University of Szeged. This work was supported by the Hungarian Academy of Sciences—ELKH-SZTE Neuroscience Research Group, University of Szeged Open Access Fund, Grant: 5706. Bernadett Tuka Ph.D. was supported by the TKP2020 Thematic Excellence Program 0 T 204 2939/211, Tamás Körtési Ph.D. was supported by the UNKP-22–4 New National Excellence Program of the Ministry for Innovation and Technology, and László Vécsei MD Ph.D. DSc was supported by the NKFIH-1279–2/2020 TKP2020 Thematic Excellence Program. AB - The glutamatergic neurotransmission has important role in the pathomechanism of primary headache disorders. The kynurenine metabolites derived from catabolism of tryptophan (Trp) have significant involvement not only in glutamatergic processes, but also in the neuroinflammation, the oxidative stress and the mitochondrial dysfunctions. Previously we identified a depressed peripheral Trp metabolism in interictal period of episodic migraineurs, which prompted us to examine this pathway in patients with episodic cluster headache (CH) as well. Our aims were to compare the concentrations of compounds both in headache-free and attack periods, and to find correlations between Trp metabolism and the clinical features of CH. Levels of 11 molecules were determined in peripheral blood plasma of healthy controls (n = 22) and interbout/ictal periods of CH patients (n = 24) by neurochemical measurements.Significantly decreased L-kynurenine (KYN, p < 0.01), while increased quinolinic acid (QUINA, p < 0.005) plasma concentrations were detected in the interbout period of CH patients compared to healthy subjects. The levels of KYN are further reduced during the ictal period compared to the controls (p < 0.006). There was a moderate, negative correlation between disease duration and interbout QUINA levels (p < 0.048, R = - 0.459); and between the total number of CH attacks experienced during the lifetime of patients and the interbout KYN concentrations (p < 0.024, R = - 0.516). Linear regression models revealed negative associations between age and levels of Trp, kynurenic acid, 3-hdyroxyanthranilic acid and QUINA in healthy control subjects, as well as between age and ictal level of anthranilic acid.Our results refer to a specifically altered Trp metabolism in CH patients. The onset of metabolic imbalance can be attributed to the interbout period, where the decreased KYN level is unable to perform its protective functions, while the concentration of QUINA, as a toxic compound, increases. These processes can trigger CH attacks, which may be associated with glutamate excess induced neurotoxicity, neuroinflammation and oxidative stress. Further studies are needed to elucidate the exact functions of these molecular alterations that can contribute to identify new, potential biomarkers in the therapy of CH. LA - English DB - MTMT ER - TY - JOUR AU - Farkas, Klaudia AU - Endre, G AU - Bacsur, Péter AU - Resál, Tamás AU - Kocsmárszky-Koósz, V AU - Tömösi, Ferenc AU - Tóth, E AU - Rutka, Mariann AU - Bálint, Anita AU - Fábián, Anna AU - Bor, Renáta AU - Szepes, Zoltán AU - Goretity, Á AU - Thibodeau, I AU - Molnár, Tamás TI - Plasma metabolite fingerprint could discriminate inflammatory bowel disease patients from healthy subjects JF - JOURNAL OF CROHNS & COLITIS J2 - J CROHNS COLITIS VL - 17 PY - 2023 IS - Supplement_1 SP - i73 EP - i76 PG - 4 SN - 1873-9946 DO - 10.1093/ecco-jcc/jjac190.0053 UR - https://m2.mtmt.hu/api/publication/33611558 ID - 33611558 N1 - Szövegében 1 oldalnál rövidebb absztrakt. LA - English DB - MTMT ER - TY - THES AU - Tömösi, Ferenc TI - Targeted metabolomics of tryptophan and its metabolites in neurological diseases [A triptofán és metabolitjainak célzott metabolomikai vizsgálata neurológiai kórképekben] PB - Szegedi Tudományegyetem PY - 2022 SP - 66 DO - 10.14232/phd.11474 UR - https://m2.mtmt.hu/api/publication/34113116 ID - 34113116 LA - English DB - MTMT ER - TY - JOUR AU - Váczi, Sándor AU - Barna, Lilla AU - Laczi, Krisztián AU - Tömösi, Ferenc AU - Rákhely, Gábor AU - Penke, Botond AU - Fülöp, Lívia AU - Bogár, Ferenc AU - Janáky, Tamás AU - Deli, Mária Anna AU - Mezei, Zsófia TI - Effects of sub-chronic, in vivo administration of sigma-1 receptor ligands on platelet and aortic arachidonate cascade in streptozotocin-induced diabetic rats JF - PLOS ONE J2 - PLOS ONE VL - 17 PY - 2022 IS - 11 PG - 23 SN - 1932-6203 DO - 10.1371/journal.pone.0265854 UR - https://m2.mtmt.hu/api/publication/33265905 ID - 33265905 LA - English DB - MTMT ER - TY - JOUR AU - Váczi, Sándor AU - Barna, Lilla AU - Laczi, Krisztián AU - Tömösi, Ferenc AU - Rákhely, Gábor AU - Penke, Botond AU - Fülöp, Lívia AU - Bogár, Ferenc AU - Janáky, Tamás AU - Deli, Mária Anna AU - Mezei, Zsófia TI - Effects of sub-chronic, in vivo administration of sigma non-opioid intracellular receptor 1 ligands on platelet and aortic arachidonate cascade in rats JF - EUROPEAN JOURNAL OF PHARMACOLOGY J2 - EUR J PHARMACOL VL - 925 PY - 2022 PG - 10 SN - 0014-2999 DO - 10.1016/j.ejphar.2022.174983 UR - https://m2.mtmt.hu/api/publication/32801748 ID - 32801748 N1 - További támogatások: ÚNKP-20-3-SZTE-503; Richter Gedeon Nyrt. Centenáriumi Alapítvány 2020/K/21/2503 LA - English DB - MTMT ER - TY - JOUR AU - Virók, Dezső AU - Tömösi, Ferenc AU - Keller-Pintér, Anikó AU - Szabó, Kitti AU - Bogdanov, Anita AU - Póliska, Szilárd AU - Rázga, Zsolt AU - Bruszel, Bella AU - Cseh, Zsuzsanna AU - Kókai, Dávid AU - Paróczai, Dóra AU - Endrész, Valéria AU - Janáky, Tamás AU - Burián, Katalin TI - Indoleamine 2,3-Dioxygenase Cannot Inhibit Chlamydia trachomatis Growth in HL-60 Human Neutrophil Granulocytes JF - FRONTIERS IN IMMUNOLOGY J2 - FRONT IMMUNOL VL - 12 PY - 2021 PG - 14 SN - 1664-3224 DO - 10.3389/fimmu.2021.717311 UR - https://m2.mtmt.hu/api/publication/32489937 ID - 32489937 N1 - FUNDING: DV, TJ, FT, and BB were supported by EFOP 3.6.1 Program. TJ, FT, and BB were supported by the Thematic Excellence Program 2020 (TKP2020-IKA-07). LA - English DB - MTMT ER - TY - CONF AU - Katona, Gábor AU - Balogh, György Tibor AU - Dargó, Gergő AU - Gáspár, Róbert AU - Márki, Árpád AU - Ducza, Eszter AU - Sztojkov-Ivanov, Anita AU - Tömösi, Ferenc AU - Kecskeméti, Gábor AU - Janáky, Tamás AU - Kiss, Tamás AU - Ambrus, Rita AU - Pallagi, Edina AU - Révész, Piroska AU - Pannonhalminé Csóka, Ildikó ED - Malgorzata, Sznitowska TI - Quality by Design based formulation of intranasal meloxicam containing human serum albumin nanoparticles T2 - 13th Central European Symposium on Pharmaceutical Technology PB - Medical University of Gdansk C1 - Gdansk PY - 2021 SP - 71 EP - 71 PG - 1 UR - https://m2.mtmt.hu/api/publication/32475125 ID - 32475125 LA - English DB - MTMT ER - TY - JOUR AU - Annus, Ádám AU - Tömösi, Ferenc AU - Rárosi, Ferenc AU - Huszár Lászlóné Fehér, Evelin AU - Janáky, Tamás AU - Kecskeméti, Gábor AU - Toldi, József AU - Klivényi, Péter AU - Sztriha, László Krisztián AU - Vécsei, László TI - Kynurenic acid and kynurenine aminotransferase are potential biomarkers of early neurological improvement after thrombolytic therapy : a pilot study JF - ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE J2 - ADV CLIN EXP MED VL - 30 PY - 2021 IS - 12 SP - 1225 EP - 1232 PG - 8 SN - 1899-5276 DO - 10.17219/acem/141646 UR - https://m2.mtmt.hu/api/publication/32382697 ID - 32382697 N1 - Department of Neurology, Albert Szent-Györgyi Health Centre, University of Szeged, Hungary Department of Medical Chemistry, University of Szeged, Hungary Department of Medical Physics and Informatics, University of Szeged, Hungary Department of Physiology, Anatomy and Neuroscience, University of Szeged, Hungary Department of Neurology, King’s College Hospital, London, United Kingdom MTA-SZTE Neuroscience Research Group, Szeged, Hungary Interdisciplinary Excellence Centre, University of Szeged, Hungary Cited By :2 Export Date: 7 March 2024 Correspondence Address: Vécsei, L.; Department of Neurology, Hungary; email: vecsei.laszlo@med.u-szeged.hu AB - Biomarkers for predicting treatment response to thrombolysis in acute ischemic stroke are currently lacking. Both, animal models and clinical studies have provided evidence that the kynurenine (KYN) pathway is activated in ischemic stroke.In our pilot study, we aimed to investigate whether KYN pathway enzymes and metabolites could serve as potential biomarkers for treatment response in the hyperacute phase of ischemic stroke.We included 48 acute ischemic stroke patients who received thrombolysis. Blood samples were taken both before and 12 h after treatment. Concentrations of 11 KYN metabolites were determined using ultra-high-performance liquid chromatography-mass spectrometry. To assess the treatment response, we used early neurological improvement (ENI), calculated as the difference between the admission and discharge National Institutes of Health Stroke Scale (NIHSS) scores. We performed receiver operating characteristic (ROC) analysis for KYN pathway metabolites and enzymes that showed a correlation with ENI.In the samples taken before thrombolysis, significantly lower concentrations of kynurenic acid (KYNA) and kynurenine aminotransferase (KAT) activity were found in patients who had ENI (p = 0.01 and p = 0.002, respectively). According to the ROC analysis, the optimal cut-off value to predict ENI for KYNA was 37.80 nM (sensitivity (SN) 69.2%, specificity (SP) 68.4%) and 0.0127 for KAT activity (SN 92.3%, SP 73.7%).Our research is the first clinical pilot study to analyze changes in the KYN pathway in ischemic stroke patients who received thrombolytic treatment. Based on our results, baseline KYNA concentration and KAT activity could serve as potential biomarkers to predict early treatment response to thrombolysis. LA - English DB - MTMT ER - TY - JOUR AU - Tuka, Bernadett AU - Nyári, Aliz AU - Cseh, Edina Katalin AU - Körtési, Tamás AU - Veréb, Dániel AU - Tömösi, Ferenc AU - Kecskeméti, Gábor AU - Janáky, Tamás AU - Tajti, János AU - Vécsei, László TI - Clinical relevance of depressed kynurenine pathway in episodic migraine patients: potential prognostic markers in the peripheral plasma during the interictal period JF - JOURNAL OF HEADACHE AND PAIN J2 - J HEADACHE PAIN VL - 22 PY - 2021 IS - 1 PG - 19 SN - 1129-2369 DO - 10.1186/s10194-021-01239-1 UR - https://m2.mtmt.hu/api/publication/32082174 ID - 32082174 N1 - Funding Agency and Grant Number: MTA-SZTE Neuroscience Research Group of the Hungarian Academy of Sciences -University of Szeged; Hungarian Brain Research Program [KTIA_13_NAP-A-III/9]; University of Szeged Open Access Fund [5108]; TKP2020 Thematic Excellence Program [0 T 204 2939/211, NKFIH-1279-2/2020]; New National Excellence Program of the Ministry for Innovation and Technology [UNKP-19-3]; [EFOP-3.6.3-VEKOP-16-2017-00009] Funding text: This work was supported by the MTA-SZTE Neuroscience Research Group of the Hungarian Academy of Sciences -University of Szeged, the Hungarian Brain Research Program: Grant No. KTIA_13_NAP-A-III/9, University of Szeged Open Access Fund, Grant: 5108. Bernadett Tuka was supported by the TKP2020 Thematic Excellence Program 0 T 204 2939/211, Edina Katalin Cseh and Tamas Kortesi were supported by the UNKP-19-3 New National Excellence Program of the Ministry for Innovation and Technology, Edina Katalin Cseh was supported by the EFOP-3.6.3-VEKOP-16-2017-00009 Program and Laszlo Vecsei was supported by the NKFIH-1279-2/2020 TKP2020 Thematic Excellence Program. LA - English DB - MTMT ER - TY - JOUR AU - Traj, Péter AU - Ali, Hazhmat AU - Motzwickler-Németh, Anett AU - Dajcs, Sámuel Trisztán AU - Tömösi, Ferenc AU - Tea, Lanisnik-Rizner AU - Zupkó, István AU - Mernyák, Erzsébet TI - Transition metal-catalyzed A-ring C–H activations and C(sp2)–C(sp2) couplings in the 13α-estrone series and in vitro evaluation of antiproliferative properties JF - JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY J2 - J ENZYM INHIB MED CH VL - 36 PY - 2021 IS - 1 SP - 895 EP - 902 PG - 8 SN - 1475-6366 DO - 10.1080/14756366.2021.1900165 UR - https://m2.mtmt.hu/api/publication/31916683 ID - 31916683 LA - English DB - MTMT ER -